CrystalGenomics/CG Pharmaceuticals announced a strategic alliance agreement with ProQuest Investments to identify and develop orally available drugs that modulate the HIF Prolyl Hydroxylase enzyme system. Under the agreement, CrystalGenomics will receive up to $6 million in upfront and initial research funding from Palkion, in addition to development and sales milestone payments of potentially more than $200 million. Release